Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, Wegovy is a once-weekly injection. You take it on the same day each week, every week, as a single subcutaneous dose. That rhythm is built into how semaglutide works — the medicine stays active in your body for roughly seven days, which is why the weekly schedule is the only licensed dosing pattern, not an option you can vary. It is a prescription-only medicine requiring a clinical assessment before treatment can begin.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A common assumption is that a more powerful medicine must mean a more frequent dose. With Wegovy, that's simply not how the pharmacology works. Semaglutide is engineered with a fatty-acid chain that binds to albumin in the bloodstream, slowing its clearance so that meaningful levels persist for around seven days after a single injection. Once that half-life was established in development, a once-weekly regimen became the natural fit, not a convenience feature, but a reflection of the drug's biology.
The semaglutide overview goes into the mechanism in more detail, but the short version is that the medicine continues suppressing appetite and slowing gastric emptying across the whole week from a single dose. You don't need to remember a daily tablet or manage multiple injection days. One fixed day (many people choose a weekend morning) and the week's dose is done.
The NHS medicines page for semaglutide confirms the once-weekly dosing schedule and explains why consistency on the same day each week supports stable blood levels.
Wegovy doesn't start at its maintenance strength. The licensed schedule begins at 0.25 mg weekly for the first four weeks, then moves through 0.5 mg, 1.0 mg and 1.7 mg in roughly four-week steps before reaching the 2.4 mg maintenance dose, a process that typically takes around seventeen weeks in total. Each rung on that ladder exists to give your digestive system time to adapt; the nausea and stomach-settling effects that some people notice are usually most noticeable right after starting or after a dose increase, and they tend to ease as the body adjusts.
From April 2026, the MHRA also approved a dedicated single-dose 7.2 mg pen as the higher maintenance option for eligible adults, a development covered in more detail on the Wegovy treatment page. The starting dose remains 0.25 mg regardless; the path to 7.2 mg is simply longer. A prescriber decides both the pace of that titration and whether the higher maintenance dose is appropriate.
One practical point worth knowing: you don't have to inject on the day you started. If your chosen day stops working (shift patterns change, travel gets in the way) you can move the injection day provided the gap between doses stays within a range your prescriber or the Patient Information Leaflet specifies. The guide to Wegovy's weekly routine covers this in full.
This is where the landscape shifted significantly in summer 2026. The MHRA approved Wegovy tablets (the first oral GLP-1 medicine licensed for weight management in the UK) on 11 June 2026. The tablet form follows a completely different rhythm: it is taken once daily, first thing in the morning on an empty stomach, with no more than a small sip of plain water, and you wait at least thirty minutes before eating, drinking or taking other medicines. The oral Wegovy page explains the full schedule and the practical differences from the injection.
So if someone asks whether Wegovy is weekly, the accurate answer is: the injection is once weekly; the tablet is once daily. They contain the same active ingredient but are distinct licensed products with different dosing schedules. Which format suits you depends on your preferences, lifestyle and what a prescriber judges clinically appropriate, it is not a straightforward swap without clinical input.
For a side-by-side look at what the weekly injection costs in private practice, the Wegovy cost page covers current market context without any of the headline-figure confusion that circulates online.
The honest answer here is that the Patient Information Leaflet and your prescriber are the authoritative guides, and that's not a dodge. The guidance on missed doses depends on how far through the week you are, what dose you're on, and whether you've had side effects at that dose before. General missed-dose advice for once-weekly medicines often involves taking it as soon as you remember if it's within a certain window, then resuming your usual day, but the specific window for semaglutide is laid out precisely in the PIL for a reason, and a prescriber can advise if you're unsure.
What the daily-versus-weekly comparison makes clear is that the weekly schedule is part of what makes adherence manageable for most people. Missing a daily tablet carries a different practical weight than missing one weekly injection. That said, consistency still matters with a weekly medicine, semaglutide works best when levels stay stable, and regularly skipping or doubling doses disrupts that. If you find yourself frequently uncertain about your schedule, that's a good reason to raise it with your prescriber at your next review.
Questions about your specific routine are exactly the kind of thing the team at our support line can help direct you to the right clinical resource for, available seven days a week as part of treatment at nume.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.